Kwality Pharmaceuticals

880.90
+7.40
(0.85%)
Market Cap
914.08 Cr
EPS
22.76
PE Ratio
25.84
Dividend Yield
0.00 %
Industry
Healthcare
52 Week High
1,069.95
52 Week Low
405.00
PB Ratio
3.77
Debt to Equity
0.45
Add Ratio
hide

Investment Returns

In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Competitors LTP Market Cap (₹ Cr.) P/E Ratio Revenue (₹ Cr.) YoY Revenue Growth % Net Profit (₹ Cr.) YoY Profit Growth % RSI
1,734.70
#1 4,16,212.64
35.22
#1 49,887.20
12.06
#1 9,648
13.77
54.74
5,775.45
1,53,320.05
75.20
8,184.00
0.89
1,600
#1 64.53
50.68
1,442.20
1,16,474.23
24.00
26,520.70
14.17
4,155
47.38
42.46
3,227.95
1,09,248.50
58.64
10,785.70
11.59
1,656
13.54
59.06
2,424.75
1,00,039.98
49.78
10,615.60
19.57
1,942
-16.38
57.16
1,144.20
95,478.38
#1 18.06
28,905.40
12.36
5,578
1.69
43.23
2,027.95
92,584.22
32.14
20,141.50
#1 19.94
1,936
38.82
48.77
886.40
89,192.58
19.77
19,831.50
13.82
3,831
29.92
41.50
1,160.50
67,402.03
19.21
29,559.20
17.55
3,169
-10.04
52.98
30,720.55
65,279.02
48.70
6,097.20
10.80
1,201
16.01
56.63
Growth Rate
Revenue Growth
21.65 %
Net Income Growth
22.28 %
Cash Flow Change
3.87 %
ROE
9.49 %
ROCE
23.34 %
EBITDA Margin (Avg.)
-11.23 %

Quarterly Financial Results

Quarterly Financials
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Revenue
121
184
89
66
71
57
57
70
68
70
79
93
80
90
85
Expenses
73
100
64
48
52
40
41
74
54
54
61
78
63
70
67
EBITDA
49
84
25
18
18
17
16
-4
14
16
17
14
18
20
18
Operating Profit %
40 %
45 %
28 %
25 %
26 %
28 %
27 %
-7 %
20 %
22 %
21 %
15 %
22 %
22 %
21 %
Depreciation
2
3
3
3
3
4
4
4
5
5
5
5
4
5
5
Interest
1
1
1
1
1
1
2
2
2
2
3
3
3
3
2
Profit Before Tax
46
80
22
14
14
12
10
-10
7
8
10
6
11
13
11
Tax
11
21
6
4
4
2
3
-2
2
2
2
2
3
4
3
Net Profit
34
60
16
11
11
9
7
-7
5
6
8
4
8
9
9
EPS in ₹
32.96
57.33
15.20
9.97
9.99
8.82
6.82
-7.23
5.10
5.99
7.39
4.08
8.04
8.15
8.21

Balance Sheet

Balance Sheet
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Total Assets
37
51
71
96
105
133
166
341
354
394
Fixed Assets
13
13
17
20
29
43
57
92
121
139
Current Assets
25
38
53
75
75
89
106
228
207
243
Capital Work in Progress
0
0
0
0
0
0
3
12
14
0
Investments
1
2
3
5
4
3
4
0
0
0
Other Assets
24
37
51
71
72
87
102
237
219
255
Total Liabilities
37
51
71
96
105
133
166
341
354
394
Current Liabilities
17
27
42
62
61
68
78
140
126
152
Non Current Liabilities
1
3
4
6
8
20
28
21
29
20
Total Equity
19
21
25
29
36
45
60
180
199
223
Reserve & Surplus
15
17
20
19
27
36
51
171
190
214
Share Capital
4
5
5
10
10
10
10
10
10
10

Cash Flow

Cash Flow
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Net Cash Flow
1
0
2
-1
-0
0
4
3
-6
-1
Investing Activities
-1
-3
-7
-6
-12
-18
-23
-63
-48
-26
Operating Activities
1
-3
4
-1
14
6
27
61
41
43
Financing Activities
1
6
5
5
-2
12
1
6
1
-17

Share Holding

% Holding
Mar 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Promoter
54.13 %
54.24 %
54.24 %
54.43 %
54.45 %
54.45 %
54.45 %
54.74 %
54.74 %
54.77 %
54.77 %
54.83 %
54.83 %
54.83 %
54.83 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
DIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.01 %
0.01 %
0.01 %
0.01 %
0.01 %
0.00 %
0.00 %
0.02 %
0.03 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
23.18 %
25.38 %
25.91 %
26.29 %
26.54 %
26.25 %
25.92 %
26.27 %
29.29 %
31.64 %
32.95 %
31.70 %
31.78 %
32.78 %
33.25 %
Others
22.69 %
20.38 %
19.84 %
19.28 %
19.01 %
19.30 %
19.63 %
18.99 %
15.96 %
13.58 %
12.27 %
13.47 %
13.40 %
12.38 %
11.90 %
No of Share Holders
148
168
379
581
1,049
4,198
5,376
6,211
6,943
6,291
5,786
5,695
5,273
7,487
8,947

Dividend History

Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %
Annual Cash Flows 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Dividend Per Share (₹) 0.00 0.6 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield (%) 0.00 1.46 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Corporate Action

Announcements

Closure of Trading Window3 days ago
Kwality Pharmaceutical Limited Receives Product Registration Of Cyclophosphamide 1Gm In MexicoFeb 14, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 04, 2025
Integrated Filing (Financial)Jan 31, 2025
UNAUDITED FINANCIAL RESULTS FOR Q.E. 31-12-2024Jan 31, 2025
Board Meeting Outcome for SUBMISSION OF UNAUDITED FINANCIAL RESULTS FOR Q.E. 31-12-2024Jan 31, 2025
KWALITY PHARMA RECEIVED SFDA APPROVAL FOR ITS GENERAL INJECTABLES AND BETA LACTAM (UNIT 1 & 2 IN AMRITSAR).Jan 21, 2025
Board Meeting Intimation for Declaring Standalone And Consolidated Unaudited Financial Results For The Quarter And Nine Months Ended December 31 2024 Along With Limited Review ReportJan 20, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jan 12, 2025
Kwality Pharmaceutical Ltd Receives RCGM Approval To Advance For Pre-Clinical Studies Of Erythropoietin (10000 IU/Ml)Jan 02, 2025
Intimation Under Regulation 30(6) Of SEBI (Listing Obligations And Disclosure Requirements), Regulations, 2015 ('SEBI Listing Regulations') - Schedule Of Analyst/ Institutional Investor MeetingNov 27, 2024
Kwality Received Its First Biological Product Permission For Manufacturing And Sale Of Pegylated-AsparaginaseNov 26, 2024
Kwality Pharma Received The Approval For Leuprorelin Acetate For Injectable Suspension As A Site Variation From GreeceNov 06, 2024
Announcement under Regulation 30 (LODR)-Newspaper PublicationNov 06, 2024
Board Meeting Outcome for Submission Of Unaudited Financial Results For The Quarter And Half Year Ended 30-09-2024Oct 30, 2024
Submission Of Unaudited Financial Results For The Quarter And Half Year Ended 30-09-2024Oct 30, 2024
Board Meeting Intimation for Consider And Approve The Unaudited Standalone And Consolidated Financial Results For The Quarter And Half Year Ended September 30, 2024.Oct 22, 2024
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018Oct 11, 2024
Closure of Trading WindowSep 29, 2024
Announcement under Regulation 30 (LODR)-Appointment of Statutory Auditor/sSep 26, 2024
Shareholder Meeting / Postal Ballot-Scrutinizer''s ReportSep 26, 2024
Proceedings Of 41St Annual General Meeting Of The Company Held On September 24, 2024Sep 24, 2024
Announcement under Regulation 30 (LODR)-Newspaper PublicationSep 04, 2024
Reg. 34 (1) Annual Report.Aug 31, 2024
Notice Of 41St Annual General Meeting Of The CompanyAug 31, 2024
41St Annual General Meeting (AGM) Of The Company Will Be Held On Tuesday, The 24Th September, 2024 At 12.00 Noon Through Video Conference (VC) / Other Audio Visual Means (OAVM)Aug 31, 2024
Intimation Of Book ClosureAug 31, 2024
Board Meeting Outcome for Intimation Of AGMAug 31, 2024
Clarification On Price MovementAug 23, 2024
Clarification sought from Kwality Pharmaceuticals LtdAug 22, 2024
Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 13, 2024
Rectification Of Typographical Error And Submission Of Revised Financial Results For The Quarter Ended 30Th June 2024Aug 12, 2024
Submission Of Standalone And Consolidated Un-Audited Financial Results For The Quarter Ended On 30.06.2024Aug 10, 2024
Board Meeting Outcome for Submission Of Standalone And Consolidated Un-Audited Financial Results For The Quarter Ended On 30.06.2024Aug 10, 2024
Board Meeting Intimation for Approval Of Standalone And Consolidated Unaudited Financial Results Of The Company For The Quarter Ended On 30Th June, 2024Aug 02, 2024
KWALITY PHARMA RECEIVED PERU- DIGEMID Approval For Its Generic, Injectable & OSD (Unit -1 In Amritsar) And Oncology, Injectable And OSD (Unit-3 In Himachal Pradesh)Jul 17, 2024
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018Jul 14, 2024
Closure of Trading WindowJun 28, 2024
Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 30, 2024
Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 27, 2024
Investor Presentation Of The Results Of The Company For The Financial Year Ended 31St March, 2024May 27, 2024
Investor Presentation Of The Results Of The Company For The Financial Year Ended 31St March, 2024May 27, 2024
Board Meeting Outcome for Audited Standalone And Consolidated Financial Results For The Quarter And Financial Year Ended 31St March, 2024May 23, 2024
FINANCIAL RESULTS FOR THE QTR AND YEAR ENDED 31ST MARCH 2024May 23, 2024
Board Meeting Intimation for Considering The Standalone & Consolidated Audited Financial Results For The 4Th Quarter And Financial Year Ended On 31St March, 2024May 08, 2024
Certificate Under Regulation 40(9) Of SEBI (Listing Obligations And Disclosure Requirements) For The Year Ended On 31St March, 2024Apr 30, 2024
KWALITY PHARMA RECEIVED INVIMA APPROVAL FOR ITS ONCOLOGY (UNIT-III) VIAL LINE AND TABLET LINEApr 29, 2024
KWALITY PHARMA RECEIVED INVIMA APPROVAL FOR ITS AMPOULE AND VIAL PRODUCT LINESApr 22, 2024
Compliance Certificate For The Year Ended On 31St March, 2024Apr 12, 2024
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018Apr 12, 2024

Technical Indicators

RSI(14)
Neutral
67.92
ATR(14)
Volatile
59.76
STOCH(9,6)
Overbought
80.12
STOCH RSI(14)
Overbought
99.15
MACD(12,26)
Bullish
28.68
ADX(14)
Strong Trend
30.42
UO(9)
Bearish
54.85
ROC(12)
Uptrend And Accelerating
33.14
WillR(14)
Overbought
-15.83